BioSpace News Archive

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020 ADAR editing advancing with additional in vivo data expected at upcoming Analyst & Investor Research Webcast Wave to host investor conference call and webcast at 8:30 a.m. ET today

Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern , MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40 th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13,

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will host its 2020 virtual Investor Day on Thursday, August 13, 2020 from 10:00 am – 12:00 pm ET . The virtual investor day will include executive presentations followed by

miR Scientific, LLC, a healthcare company whose purpose is to transform cancer management by providing early and highly accurate detection, characterization and monitoring of disease, today announced that validation data for its Sentinel Prostate Test™ a urine-based, non-invasive cancer test were published in the September issue of the Journal of Urology.

- Primary endpoint met assessing safety and tolerability in the Phase 1b monotherapy portion of the study - - Preliminary results demonstrate an encouraging trend in C-peptide levels, a biomarker for T1D disease progression - - Preliminary data shows an increase in the frequency of islet-specific Tregs, a potential mechanistic indicator of therapeutic activity - [10-August-2020]

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI); (OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and six months ended June 30, 2020.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has signed a binding memorandum of understanding (“MOU”) with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division (“Jubila